Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC.
Company profile
Website
CEO
Neal F. Fowler
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Latest filings (excl ownership)
15-12B
Securities registration termination
30 Nov 20
EFFECT
Notice of effectiveness
23 Nov 20
EFFECT
Notice of effectiveness
23 Nov 20
25-NSE
Exchange delisting
18 Nov 20
POS AM
Prospectus update (post-effective amendment)
18 Nov 20
POS AM
Prospectus update (post-effective amendment)
18 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Nov 20
Transcripts
Earnings call transcript
2020 Q4
23 Mar 21
Earnings call transcript
2020 Q3
9 Nov 20
Earnings call transcript
2020 Q2
10 Aug 20
Earnings call transcript
2020 Q1
11 May 20
Earnings call transcript
2019 Q4
11 Mar 20
Earnings call transcript
2019 Q3
13 Nov 19
Earnings call transcript
2019 Q2
8 Aug 19
Earnings call transcript
2019 Q1
6 May 19
Earnings call transcript
2018 Q4
26 Feb 19
Earnings call transcript
2018 Q3
31 Oct 18
Latest ownership filings
SC 13G/A
ArrowMark Colorado Holdings LLC
16 Feb 21
4
FREDRIC N ESHELMAN
27 Nov 20
4
FREDRIC N ESHELMAN
25 Nov 20
4
FREDRIC N ESHELMAN
24 Nov 20
4
FREDRIC N ESHELMAN
20 Nov 20
144
Notice of proposed sale of securities
20 Nov 20
3
Steven Bariahtaris
21 Aug 20
SC 13D/A
New Enterprise Associates 12, Limited Partnership
7 Jul 20
4
FREDRIC N ESHELMAN
2 Jul 20
4
Stephen M Bloch
23 Jun 20
Financial summary
Quarter (USD) | Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 19 | Dec 18 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q3 2023
58.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 108 |
Opened positions | 18 |
Closed positions | 18 |
Increased positions | 31 |
Reduced positions | 34 |
13F shares | Current |
---|---|
Total value | 182.78 bn |
Total shares | 37.75 mm |
Total puts | 390.70 k |
Total calls | 639.10 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Caligan Partners | 9.24 mm | $58.60 bn |
BLK Blackrock | 3.31 mm | $20.96 bn |
Canaan VIII | 2.92 mm | $0.00 |
Vanguard | 2.77 mm | $17.59 bn |
New Enterprise Associates 12, Limited Partnership | 2.53 mm | $0.00 |
Kynam Capital Management | 2.00 mm | $12.68 bn |
Eshelman Ventures | 1.88 mm | $5.51 mm |
Eversept Partners | 1.40 mm | $8.85 bn |
Xeraya LT | 1.40 mm | $4.12 mm |
STT State Street | 1.05 mm | $6.67 bn |